Skin darkening in dialysis patients results from a buildup of pigments and hormones that healthy kidneys normally filter out or break down. The change can range from a subtle yellow-brown hue to a pronounced, diffuse blackish discoloration, and it tends to be most visible on sun-exposed areas like the face, hands, and forearms. The underlying causes are not as simple as one molecule gone rogue: several overlapping biochemical processes work together, and the specifics of dialysis treatment, medications, and even iron therapy can all play a role.
The Hormone That Drives Melanin Production
The single biggest contributor to skin darkening in dialysis patients is an abnormal surge in melanocyte-stimulating hormones, particularly beta-melanocyte-stimulating hormone (β-MSH). These hormones tell the pigment-producing cells in your skin to make more melanin, the same molecule that gives you a suntan. In people with healthy kidneys, these hormones are produced in small amounts and cleared efficiently. When the kidneys fail, that clearance mechanism breaks down and the hormones pile up in the blood.
Research from the 1970s first documented this clearly, finding that plasma melanotrophic hormone levels in maintenance hemodialysis patients were dramatically elevated, ranging from about 125 to 1,100 ng/L compared with 12 to 36 ng/L in healthy adults. Those levels correlated with how long a person had been on dialysis, and patients with the highest concentrations had the most noticeable skin darkening, especially on sun-exposed skin.1Br Med J. Plasma immunoreactive melanotrophic hormones in patients on maintenance haemodialysis That is a staggering increase, sometimes more than 30 times the normal upper limit, which explains why the color change can be so visible.
There is an interesting wrinkle here. Alpha-MSH, a related melanocyte-stimulating hormone, also rises in dialysis patients. But research has shown that α-MSH levels are not elevated in people with chronic renal failure who have not yet started dialysis, which suggests the increase is not simply from reduced kidney clearance alone. Something about the dialysis process itself, or the advanced stage of disease requiring it, triggers additional hormonal changes.2PubMed. Plasma concentrations of alpha-melanocyte-stimulating hormone are elevated in patients on chronic haemodialysis Researchers have speculated that chronic inflammation, the bioincompatibility of dialysis membranes, and the stress of repeated treatments could all contribute, though the exact trigger remains an area of active study.
Urochrome, Carotenoids, and the Yellowish Tinge
Not all of the color change in dialysis patients looks the same. Before the skin becomes overtly dark, many patients develop a yellowish or sallow tone. This comes from a different set of pigments entirely: urochrome and carotenoids. Urochrome is a waste pigment that normally exits the body through urine. Carotenoids are plant-derived pigments you absorb from foods like carrots and sweet potatoes. Both are normally metabolized or excreted by the kidneys. When that process stalls, they accumulate in the skin and subcutaneous fat, producing a distinctive yellow cast that is sometimes mistaken for jaundice.3Actas Dermo-Sifiliográficas. Skin manifestations of chronic kidney disease
This yellowish tone often coexists with the melanin-driven darkening, which is why the overall skin color in advanced kidney disease can look muddy or gray-brown rather than purely darker. The two pigment pathways layer on top of each other. Urochrome and carotenoid buildup starts earlier in the course of kidney disease, while the hormone-driven melanin increase becomes more prominent once a patient is on long-term dialysis.
How Common Is It, and Where Does It Show Up
Skin darkening is one of the most frequently reported skin changes in hemodialysis patients. One study of hemodialysis patients found diffuse blackish hyperpigmentation in about 40% of participants, predominantly in sun-exposed areas. The investigators noted this was relatively high compared with rates of 20 to 22 percent reported in some earlier studies, and attributed the difference partly to the failure of the kidneys to excrete β-MSH, with the resulting melanin being deposited in both the outermost layer of skin and the layer just beneath it.4PubMed Central. Cutaneous Manifestations in Patients with Chronic Kidney Disease on Maintenance Hemodialysis Other studies have reported even higher prevalence rates, with hyperpigmentation present in roughly three out of four hemodialysis patients in some populations.
The predilection for sun-exposed skin is not a coincidence. Ultraviolet radiation stimulates melanocytes to produce melanin under normal circumstances. When those melanocytes are already being driven into overdrive by elevated melanotrophic hormones, the added UV stimulus amplifies the effect. This is why the forehead, the backs of the hands, and the forearms often darken more dramatically than covered areas like the abdomen or inner arm. It also means that dialysis patients who spend more time outdoors, or who live in sunnier climates, tend to show more pronounced darkening than those who do not.
Advanced Glycation End Products and Skin Aging
Beyond pigment and hormones, there is a subtler process happening in the skin of people with chronic kidney disease: the accumulation of advanced glycation end products, or AGEs. These are chemically modified proteins formed when sugars react spontaneously with proteins in the body. Everyone accumulates some AGEs with age, but in kidney disease the process accelerates dramatically because the kidneys can no longer clear these molecules effectively. Levels of AGE fragments in the blood rise steeply as kidney filtration declines.5PubMed Central. Advanced glycation end products in the pathogenesis of chronic kidney disease
AGEs do not cause pigmentation in the way melanin does. Instead, they cross-link with collagen and other structural proteins in the skin, making it stiffer and giving it a brownish, aged appearance. If you have ever noticed that very old parchment or well-worn leather takes on a yellowish-brown tint, the mechanism is similar: sugar-protein reactions that slowly discolor tissue. This cross-linking contributes to the overall dull, darkened look of the skin in dialysis patients and also makes the skin less elastic and more fragile.
Does the Type of Dialysis Make a Difference
Dialysis comes in several forms, and patients naturally wonder whether switching between them might help their skin. The two main options are hemodialysis, where blood is filtered through a machine, and peritoneal dialysis, where a fluid-filled abdominal cavity does the filtering. Research comparing the two has found that hemodialysis and peritoneal dialysis patients end up with similar levels of skin darkness in both sun-exposed and non-sun-exposed areas.6PubMed. Quantitative comparison of skin colors in patients with ESRD undergoing different dialysis modalities In other words, the modality by itself does not seem to matter much.
There is one exception worth noting: hemodiafiltration, or HDF, a more intensive form of hemodialysis that uses both diffusion and convection to clear a wider range of waste molecules. A study comparing HDF to standard low-flux hemodialysis over 12 months found that patients on HDF showed a measurable decrease in melanin and redness on the forehead, while those on standard hemodialysis did not. The reduction in skin pigmentation correlated with better clearance of β2-microglobulin, a middle-sized molecule that standard dialysis removes poorly.7PubMed. The impact of dialysis modality on skin hyperpigmentation in haemodialysis patients This suggests that more effective removal of larger uremic toxins can, over time, partially reverse hyperpigmentation. The improvement was modest but statistically significant, and it provides a plausible mechanism: the bigger molecules that standard dialysis leaves behind include the very hormones and pigment precursors responsible for skin darkening.
Iron Therapy, Medications, and Iatrogenic Darkening
Dialysis patients almost universally receive iron supplementation, because kidney failure causes anemia and dialysis itself results in ongoing blood loss. Most of this iron is given intravenously. While iron supplementation is essential, it adds another potential layer to skin discoloration. Excess iron can deposit in tissues, and if intravenous iron accidentally leaks outside the vein during infusion, it can cause a dramatic, localized brownish-gray stain that persists for months or even permanently.
Medications commonly prescribed in kidney disease can also contribute. Some antibiotics, for example, have iron-containing metabolites that the kidneys would normally excrete. When kidney function is absent or severely impaired, these metabolites can accumulate and promote melanin synthesis or deposit directly in the skin.8Journal of Research in Medical and Dental Science. Drug Induced Hyperpigmentation Changes in a Chronic Kidney Disease This is particularly relevant when a drug is given at doses that do not account for the kidney’s inability to clear it. Drug-induced hyperpigmentation in kidney disease is often overlooked because it gets lumped in with the general darkening patients already experience, but it is worth flagging with your doctor if the color change seems sudden or patchy rather than gradual and diffuse.
Porphyria and Photosensitivity
A less common but clinically important cause of skin changes in dialysis patients is porphyria cutanea tarda, a condition where porphyrins, molecules involved in making hemoglobin, accumulate to toxic levels. In healthy people, excess porphyrins are excreted through the kidneys. Dialysis patients lose that excretion route, and dialysis itself is poor at removing porphyrins.9PubMed Central. Porphyria Cutanea Tarda in a Patient with End-Stage Renal Disease: A Case of Successful Treatment with Deferoxamine and Ferric Carboxymaltose
The hallmark of porphyria cutanea tarda is extreme photosensitivity: blisters, skin fragility, and scarring on sun-exposed areas, followed by darkening of the affected skin as it heals. It can look similar to the general hyperpigmentation of dialysis, but the blistering distinguishes it. Elevated iron stores, which are common in dialysis patients receiving regular iron infusions, worsen the condition. Treatment typically involves reducing iron levels, sometimes with the chelating agent deferoxamine, and strict sun avoidance. If you are on dialysis and notice blisters on the backs of your hands or forearms that seem triggered by sunlight, this is worth mentioning to your nephrologist or dermatologist.
Itching, Dryness, and the Full Spectrum of Skin Problems
Darkening is just one piece of a larger skin story in dialysis. Dry skin is almost universal, and itching, or uremic pruritus, affects a large fraction of patients. In one study, 187 out of the enrolled dialysis patients had dry skin, and 109 had pruritus simultaneously. The itching ranged from mild to severe enough to interfere with sleep. Regular, effective dialysis alleviated the pruritus in about 40% of patients, but roughly a third had poor results from treatment.10Spandidos Publications. Clinical features and risk factors of pruritus in patients with chronic renal failure
The itch is driven by different factors than the darkening: elevated phosphorus, calcium-phosphorus product, and parathyroid hormone all play roles. But the conditions interact. Chronic scratching damages the skin, promotes inflammation, and can itself lead to localized darkening through a process called post-inflammatory hyperpigmentation. So even though pruritus and hyperpigmentation have distinct mechanisms, the scratching that accompanies itching can make darkened patches worse in specific areas. Aggressive moisturizing, phosphorus control, and itch-targeted therapies like gabapentin or UV-B phototherapy can break this cycle for some patients.
How Skin Darkening Affects Self-Image
Clinicians tend to focus on the biochemistry, but for many patients the most pressing concern about skin darkening is how it looks and what it signals to others. Dialysis patients already deal with visible changes like fistula scars, fluid-related weight fluctuations, and fatigue. Adding widespread skin discoloration can compound feelings of self-consciousness. Research on body image in dialysis patients has found that they report elevated levels of psychological distress, and that body-image disturbance is significantly associated with that distress.11PubMed. Body-image disturbance in adult dialysis patients
This is not a trivial point. The appearance changes of dialysis are visible to family, coworkers, and strangers in ways that internal symptoms like fatigue or nausea are not. Patients sometimes describe feeling like their disease is written on their face. Dermatological support, cosmetic camouflage options, and acknowledgment from the care team that appearance matters can make a meaningful difference in how patients cope with long-term treatment.
Can the Darkening Be Reversed
The most definitive reversal comes from a successful kidney transplant. When a new kidney takes over filtration, the buildup of melanotrophic hormones, urochrome, and other pigments gradually resolves. Skin color typically lightens over weeks to months post-transplant, though some residual discoloration can persist if the darkening has been severe and long-standing, particularly where AGE cross-linking has permanently altered the dermal matrix.
Short of transplant, the HDF findings discussed earlier suggest that more aggressive toxin removal can modestly reduce pigmentation over time.7PubMed. The impact of dialysis modality on skin hyperpigmentation in haemodialysis patients Sun protection is another straightforward measure: since UV exposure amplifies the hormonal pigmentation signal, consistent sunscreen use and protective clothing can limit darkening in exposed areas. No topical lightening cream addresses the underlying hormonal cause, and dermatologists generally advise against aggressive bleaching agents in this population because the skin is already compromised by dryness and fragility.
Practical steps that help include optimizing dialysis adequacy, managing iron stores carefully to avoid overload, controlling secondary hyperparathyroidism which drives some skin changes, and maintaining skin hydration to limit the scratching cycle that worsens localized discoloration. None of these reverse the color change dramatically on their own, but together they can slow progression and preserve skin integrity.
How Clinicians Measure the Change
If you have ever wondered how researchers quantify something as subjective as skin color, the standard tool in this field is a narrow-band reflectance spectrophotometer. It shines specific wavelengths of light onto the skin and measures how much is reflected back, producing a melanin index and an erythema index (redness). Researchers typically measure several sites, both sun-exposed like the forehead and non-sun-exposed like the inner forearm or abdomen, to separate the effects of UV exposure from the underlying disease process.12Nephrology Dialysis Transplantation. The impact of dialysis modality on skin hyperpigmentation in haemodialysis patients This objective measurement has been helpful in confirming what patients report subjectively and in testing whether interventions like HDF actually make a difference rather than relying on visual impressions alone.
For patients, the takeaway is that the darkening is real, measurable, and understood well enough that the medical community can track it objectively. It is not psychosomatic, and it is not “just aging.” If your skin has changed noticeably since starting dialysis, that change has identifiable, treatable causes, even if the treatment options remain imperfect.